Projektnummer

N000767

Zusammenfassung

Lung fibrosis is responsible for 10 billion Euro health care costs and in Europe about 750.000 individuals suffer from it. Idiopathic pulmonary fibrosis (IPF) is the most common manifestation with an estimated median survival time of 3 years and a variable course. The number of deaths due to fibrosis is two times higher than that of cancer. After more than 2 decades of frustrating research, available therapies only increase median survival of treated patients to 4.5 - 5 years. A major part of the difficult drug development history for IPF is caused by major limitations of available mod...